Invea Therapeutics (INAI) IPO Price Prediction: Will INAI Stock Explode Post-IPO?

Last updated: 12/16/2025 11:01

Invea Therapeutics, a biotech company developing drugs for conditions such as psoriasis, has filed for an IPO on the Nasdaq stock exchange. Fueled by the IPO news, a lot of investors are shifting their focus to this promising company. As the company prepares to list on the Nasdaq under the ticker symbol “INAI,” traders and long-term investors alike are asking: What will Invea Therapeutics stock be worth? Is it a wise investment?

This article provides a comprehensive analysis of Invea Therapeutics’s business model, IPO details and market significance, as well as Invea Therapeutics IPO stock price predictions, thus helping investors decide whether investing in INAI stock aligns with their strategic financial goals.

Table of Contents

What is Invea Therapeutics: A Quick Business Overview
Invea Therapeutics IPO: A Full Review of Its IPO Journey
What’s the Significance of Invea Therapeutics IPO?
Invea Therapeutics (INAI) IPO Price Prediction
Should You Buy INAI Stock After IPO?
Conclusion
About BTCC

＼Unlock Up To 10,055 USDT In Welcome Rewards!／

Sign Up BTCC Now

What is Invea Therapeutics: A Quick Business Overview

Founded in 2021, Invea Therapeutics is a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs. With a target of aim developing oral, safe and effective small molecule therapies that control inflammation, prevent tissue damage, improve quality of life and achieve long-term disease remission, Invea Therapeutics is tackling immune-mediated inflammatory diseases or IMIDs which include atopic dermatitis, psoriasis, and inflammatory bowel disease.

Invea Therapeutics currently have two product candidates, INVA8001, which we plan to progress into Phase 2b of clinical development, and INVA8003, which is in early-stage preclinical development. The company plans to file a clinical trial application (CTA) in the second half of 2026 for a Phase 2a study in chronic inducible urticaria in the EU, leveraging quantitative provocation testing (TempTest) at Fraunhofer/Charité in Berlin.

Invea’s discovery efforts use the AlphaMeld AI/ML platform (licensed from its parent, InveniAI) to identify targets and candidates. The company is pre‑revenue, early‑stage, and has licensed INVA8001 (formerly ASB17061) from Daiichi Sankyo, which completed prior SAD, MAD, and a Phase 2 trial in atopic dermatitis.

[TRADE_PLUGIN]BTCUSDT,ETHUSDT[/TRADE_PLUGIN]

Invea Therapeutics IPO: A Full Review of Its IPO Journey

Invea Therapeutics initially filed its registration statement with the SEC in 2023, signaling its intention to raise $75 million in capital through a Nasdaq IPO under the symbol INAI. The company pursued this strategy to fund its clinical development programs and expand its pipeline beyond the early research stage.

However, in late March 2024, Invea withdrew its IPO registration, thereby delaying its public offering timeline. Such withdrawals are not uncommon in the biotech sector—companies sometimes pause public filings to adjust valuation expectations, improve clinical data or wait for more favorable market conditions.

On 12 December 2025, Invea Therapeutics filed an S-1 for an initial public offering on the Nasdaq Capital Market under the ticker symbol ‘INAI’. ThinkEquity is the sole bookrunner for the deal. As of press time, the price range and share count have not been disclosed.

＼Unlock Up To 10,055 USDT In Welcome Rewards!／

Sign Up BTCC Now

What’s the Significance of Invea Therapeutics IPO?

Despite concerns about the impact of President Trump’s tariffs, there has been a revival in IPOs since mid-2025. This has been driven by greater economic confidence in the US and lower interest rates, which have increased investor interest. Invea Therapeutics’ IPO comes at a time when the US IPO market is attempting a broader revival, following a sluggish year characterized by a prolonged government shutdown.

Unlike established drug developers with revenue streams, Invea currently relies heavily on external funding to finance trials and regulatory pathways. Going public could unlock tens of millions of dollars to fund mid-stage trials of INVA8001 and INVA8003. A successful listing could increase visibility among partners, potential acquirers and institutional biotech investors — a significant benefit for companies operating in competitive therapeutic areas such as IMIDs.

The broader biotech IPO market has been cyclical, with improved sentiment in 2025 compared to earlier years. According to industry reports, the biopharma sector has raised several billion dollars through public offerings each year, demonstrating renewed investor interest in therapeutic innovation. However, biotech offerings are heavily judged on clinical catalysts, trial data and regulatory clarity, all of which are highly uncertain. This backdrop shapes both the upside potential and the downside risk for INAI stock.

Invea Therapeutics (INAI) IPO Price Prediction

Invea Therapeutics has not yet disclosed the size or proposed price range for its offering. However, if Invea launches its IPO in a favourable biotech market and raises capital at a valuation comparable to that of similar early-stage biotech offerings (often in the $300–600 million pre-money range), the IPO price is predicted to be between $12 and $18 per share, based on comparable listings for clinical-stage firms.

Nevertheless, this prediction is speculative, as INAI IPO price depends on several factors, including the number of shares issued, the extent of dilution, and the underwriters’ assessment of demand. We will update this article with further information as it becomes available.

[TRADE_PLUGIN]BTCUSDT,ETHUSDT[/TRADE_PLUGIN]

Should You Buy INAI Stock After IPO?

Investing in INAI stock following its IPO requires careful consideration of the opportunities and risks associated with early-stage biotech companies. Invea Therapeutics operates in the highly competitive field of immune-mediated inflammatory diseases (IMIDs), where scientific innovation can lead to substantial gains, but clinical uncertainty remains high. Market sentiment towards biotech has shown gradual improvement alongside easing rate expectations, which could support IPOs with differentiated pipelines, such as Invea’s. However, near-term performance will depend largely on clinical execution rather than on broader market momentum alone.

As with most clinical-stage biotechnology listings, INAI’s post-IPO trajectory will be driven by trial progress, regulatory clarity and financial prudence. Investors should recognise that valuation swings are often catalyst-driven: positive Phase 2 data or partnership announcements could meaningfully re-rate the stock, while delays or negative results may put pressure on the share price. Below is a balanced view of the key benefits and risks to consider before making an investment decision.

Benefits to Consider	Risks to Weigh
Innovative pipeline with large addressable markets: Invea’s focus is on chronic inflammatory conditions where there is a significant unmet medical need. If its lead candidates demonstrate strong efficacy and safety, this could significantly increase its commercial potential and support long-term valuation expansion.	Clinical and regulatory uncertainty: As a pre-revenue, clinical-stage company, Invea’s value is extremely sensitive to the outcomes of its trials. Any setbacks in clinical development or adverse regulatory feedback could have a significant impact on the stock price.
AI-driven drug discovery approach: Invea’s use of AI and machine learning in target identification and molecule optimisation could improve R&D efficiency compared with traditional biotech models, potentially shortening development timelines and improving success rates.	Valuation sensitivity post-IPO: Biotech IPOs often experience volatility as the market reassesses fair value once trading begins. If INAI debuts at a premium valuation without any near-term catalysts, the stock price could fall.
Improving biotech market sentiment: As capital markets gradually reopen to healthcare and biotech IPOs, successful listings and renewed investor appetite could create a favourable environment for INAI shares after the IPO, especially if risk appetite continues to increase.	Financing and dilution risk: Continued R&D will likely require additional capital to be raised. Future equity offerings could dilute existing shareholders, particularly if market conditions deteriorate or clinical timelines are extended.

＼Unlock Up To 10,055 USDT In Welcome Rewards!／

Sign Up BTCC Now

Conclusion

Invea Therapeutics occupies an intriguing niche within the biotech landscape. Armed with AI-driven discovery tools and promising small molecule programs targeting a broad class of inflammatory diseases, the company is well positioned to make significant contributions to the field. Although its IPO has yet to materialize, renewed filing activity and continued clinical progress suggest that the company may pursue the public markets once it has advanced key catalysts and investor sentiment has improved.

Predicted IPO pricing remains uncertain, but it could vary significantly depending on timing, clinical data and broader market conditions. For investors considering participating in the company after its IPO, the stock’s performance will depend less on the IPO price and more on clinical milestones, regulatory progress and the effectiveness of capital deployment. As with any investment that bridges the gap between the biotech and public markets, thorough due diligence on treasury strategy, regulatory stance and the health of the medical market is essential before committing capital.

[TRADE_PLUGIN]BTCUSDT,ETHUSDT[/TRADE_PLUGIN]

About BTCC

BTCC is a trusted and well-respected exchange around the world thanks to its unwavering commitment to security and transparency. Since its establishment in 2011, BTCC has boasted an impeccable security track record, with zero reported hacks or breaches. Holding licenses in the U.S., Canada, and Europe, BTCC provides a comprehensive suite of trading features within a secure and regulated platform.

With a mission of providing a trading platform that is fair and reliable in every sense, BTCC platform supports spot trading for over 360 cryptocurrencies, crypto futures trading with leverage up to 500x, crypto copy trading that allows users to follow experienced traders, demo trading accounts pre-loaded with $100,000 in virtual funds, and tokenized futures for stocks and commodities. If you want to engage in cryptocurrency trading, you can start by signing up for BTCC.

BTCC Benefits⇓

BTCC offers a sign-up bonus for new users. Register now and start trading to receive your welcome rewards of up to 10,055 USDT. Additionally, VIP menbers can enjoy more benefits. Please note that your VIP level will increase based on your deposit amount. The more you deposit, the higher your level will be.

BTCC is among the best and safest platforms to trade cryptos in the world. The reasons why we introduce BTCC for you summarize as below:

Industry-leading Security With A Zero-hacking Record Since Its Establishment
High Leverage Of Up To 500x
High Liquidity & Volume
Extremely Low Fees
High and Rich Bonus (up to 10,055 USDT)
Excellent Customer Service
＼Unlock Up To 10,055 USDT In Welcome Rewards!／

Sign Up BTCC Now